A Tissue-Targeted Immunotherapy Protects Against Recurrent Ocular Herpes Infection and Disease, and Alleviates the Associated Cognitive, Behavioral, and Social Deficits in a 'Humanized' HLA Transgenic Mouse Model of UVB-Induced Reactivation
Karan, S.; Prakash, S.; Chentoufi, A. A.; Intharachalit, K.; Ng, S. X. L.; Hwang, J.; Maurya, C.; BENMOHAMED, L.
Show abstract
Background: Recurrent ocular herpetic disease is a leading infectious cause of corneal blindness and is associated with psychological distress, anxiety, and social withdrawal. No ocular herpes vaccine or immunotherapy currently exists. Hypothesis: A prime/pull/keep (PPK) T-cell immunotherapy, built on HSV-1 epitopes preferentially recognized by CD8+/CD4+ T cells from naturally protected asymptomatic (ASYMP) individuals, would reduce viral reactivation, shedding, recurrent corneal disease, and associated neurobehavioral deficits. Methods: Immunodominant HLA-restricted CD8+/CD4+ epitopes from HSV-1 gD/gB, tegument proteins VP11/12/VP13/14, and helicase UL9 were delivered via topical ocular AAV8 vector (prime) to latently infected HLA-A*0201/DRB1 mice, combined with chemokine CXCL11 (pull) and IL-2/IL-15 cytokines to sustain TRM cells (keep), then UVB-exposed to trigger reactivation and recurrent corneal disease. Results: PPK immunotherapy conferred robust, near-complete protection against recurrent HSV-1 disease and improved survival after UVB-induced reactivation, unlike its individual components. This protection was associated with site-specific accumulation of HSV-1-specific CD8+/CD4+ TRM cells in the cornea and trigeminal ganglia (TG), but not in the spleen, with peak retention from combined IL-2/IL-15, alongside durable central/effector memory populations. PPK-induced T cells showed enhanced polyfunctionality (cytokine production, cytotoxicity, proliferation), reduced exhaustion markers, and a TCF-1+ self-renewing phenotype. PPK also elicited robust, Th1-biased HSV-1-specific IgG responses complementing mucosal immunity, and restored spatial memory, reduced depression-like behavior, and reversed social withdrawal in mice with recurrent ocular herpes. Conclusion: PPK immunotherapy induces potent, durable antiviral TRM cells at primary sites of HSV-1 latency and reactivation, protecting against recurrent ocular herpetic disease and alleviating associated neurobehavioral deficits, supporting its translational potential in humans.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Antibodies targeting HSV glycoprotein B require effector functions to protect neonatal mice 94%
- Therapeutic Prime/Pull Vaccination of HSV-2 Infected Guinea Pigs with the Ribonucleotide Reductase 2 (RR2) Protein and CXCL11 Chemokine Boosts Antiviral Local Tissue-Resident and Effector Memory CD4+ and CD8+ T Cells and Protects Against Recurrent Genital Herpes 93%
- Antiviral CD19+CD27+ Memory B Cells Are Associated with Protection from Recurrent Asymptomatic Ocular Herpes Infection 93%
Similar papers in this journal
- Healing of Primary and Recurrent Mouse Ocular Herpetic Disease Following Topical Ocular Treatment with an Engineered Fibroblast Growth Factor-1 (FGF-1) is Associated with Increased Frequency and Function of Corneal Anti-Inflammatory M2 Macrophages 94%
- Comparison of the mucosal and systemic antibody responses in Covid-19 recovered patients with one dose of mRNA vaccine and unexposed subjects with three doses of mRNA vaccines 90%
- Immune and behavioral correlates of protection against symptomatic post-vaccination SARS-CoV-2 infection 90%
Similar papers in this journal
- IL-23 drives uveitis by acting on a novel population of tissue-resident entheseal T cells 91%
- Disruption of innate defense responses by endoglycosidase HPSE promotes cell survival 89%
- Pneumococcal colonization impairs nasal and lung mucosal immune responses to Live Attenuated Influenza Vaccination in adults 89%
Similar papers in this journal
- COVID-19 convalescents exhibit deficient humoral and T cell responses to variant of concern Spike antigens at 12 month post-infection 89%
- Protective antibodies and T cell responses to Omicron variant three months after the booster dose of BNT162b2 vaccine 89%
- GRAd-COV2 vaccine provides potent and durable immunity in randomised placebo-controlled phase 2 trial (COVITAR) 89%
Similar papers in this journal
- Mucosal CD8+ T cell responses induced by an MCMV based vaccine vector confer protection against influenza challenge 91%
- A bivalent CMV vaccine formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice 91%
- Pre-vaccination Frequency of Circulatory Tfh is associated with Robust Immune Response to TV003 Dengue Vaccine 90%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.